Ilyang Pharmaceutical Co.,Ltd (007570.KS)
KRW 10880.0
(-2.07%)
KRW 10880.0
(-2.07%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 6.05 Billion KRW | 725.72% |
| 2022 | 732.69 Million KRW | -87.51% |
| 2021 | 5.86 Billion KRW | 1851.05% |
| 2020 | 300.61 Million KRW | -98.41% |
| 2019 | 18.9 Billion KRW | -27.8% |
| 2018 | 26.18 Billion KRW | 275.55% |
| 2017 | 6.97 Billion KRW | -64.93% |
| 2016 | 19.88 Billion KRW | -35.28% |
| 2015 | 30.72 Billion KRW | -52.93% |
| 2014 | 65.27 Billion KRW | 20.65% |
| 2013 | 54.09 Billion KRW | -13.16% |
| 2012 | 62.29 Billion KRW | 3.88% |
| 2011 | 59.96 Billion KRW | 317.17% |
| 2010 | 14.37 Billion KRW | -70.99% |
| 2009 | 49.55 Billion KRW | 19.41% |
| 2008 | 41.5 Billion KRW | -17.53% |
| 2007 | 50.32 Billion KRW | 95.69% |
| 2006 | 25.71 Billion KRW | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 6.31 Billion KRW | 3.95% |
| 2024 Q1 | 6.07 Billion KRW | 0.33% |
| 2023 FY | 6.05 Billion KRW | 725.72% |
| 2023 Q4 | 6.05 Billion KRW | 12000.0% |
| 2023 Q3 | 50 Million KRW | -91.81% |
| 2023 Q2 | 610.82 Million KRW | 12.44% |
| 2023 Q1 | 543.25 Million KRW | -25.85% |
| 2022 Q4 | 732.69 Million KRW | -74.98% |
| 2022 Q3 | 2.92 Billion KRW | -47.37% |
| 2022 FY | 732.69 Million KRW | -87.51% |
| 2022 Q1 | 5.69 Billion KRW | -2.84% |
| 2022 Q2 | 5.56 Billion KRW | -2.36% |
| 2021 Q4 | 5.86 Billion KRW | 8.53% |
| 2021 Q1 | 5.44 Billion KRW | 1710.9% |
| 2021 Q2 | 5.46 Billion KRW | 0.47% |
| 2021 Q3 | 5.4 Billion KRW | -1.2% |
| 2021 FY | 5.86 Billion KRW | 1851.05% |
| 2020 Q4 | 300.61 Million KRW | -97.1% |
| 2020 Q1 | 10.48 Billion KRW | -44.52% |
| 2020 Q3 | 10.37 Billion KRW | -0.49% |
| 2020 FY | 300.61 Million KRW | -98.41% |
| 2020 Q2 | 10.42 Billion KRW | -0.64% |
| 2019 Q2 | 23.96 Billion KRW | -8.99% |
| 2019 FY | 18.9 Billion KRW | -27.8% |
| 2019 Q4 | 18.9 Billion KRW | -20.06% |
| 2019 Q3 | 23.65 Billion KRW | -1.3% |
| 2019 Q1 | 26.32 Billion KRW | 0.55% |
| 2018 Q3 | 30.74 Billion KRW | -1.73% |
| 2018 Q4 | 26.18 Billion KRW | -14.85% |
| 2018 FY | 26.18 Billion KRW | 275.55% |
| 2018 Q1 | 22.68 Billion KRW | 225.35% |
| 2018 Q2 | 31.29 Billion KRW | 37.94% |
| 2017 FY | 6.97 Billion KRW | -64.93% |
| 2017 Q3 | 9.9 Billion KRW | -10.79% |
| 2017 Q2 | 11.1 Billion KRW | -40.43% |
| 2017 Q1 | 18.64 Billion KRW | -6.23% |
| 2017 Q4 | 6.97 Billion KRW | -29.63% |
| 2016 Q1 | - KRW | 0.0% |
| 2016 Q3 | 26 Billion KRW | -31.4% |
| 2016 Q2 | 37.91 Billion KRW | 0.0% |
| 2016 FY | 19.88 Billion KRW | -35.28% |
| 2016 Q4 | 19.88 Billion KRW | -23.55% |
| 2015 FY | 30.72 Billion KRW | -52.93% |
| 2015 Q3 | - KRW | -100.0% |
| 2015 Q2 | 48.23 Billion KRW | -26.1% |
| 2015 Q1 | 65.27 Billion KRW | 0.0% |
| 2014 FY | 65.27 Billion KRW | 20.65% |
| 2014 Q2 | 52.76 Billion KRW | -2.46% |
| 2014 Q4 | - KRW | -100.0% |
| 2014 Q3 | 58.19 Billion KRW | 10.3% |
| 2014 Q1 | 54.09 Billion KRW | 0.0% |
| 2013 FY | 54.09 Billion KRW | -13.16% |
| 2013 Q1 | 62.29 Billion KRW | -7.48% |
| 2012 Q4 | 67.33 Billion KRW | 0.0% |
| 2012 Q3 | - KRW | 0.0% |
| 2012 Q1 | 59.96 Billion KRW | -3.28% |
| 2012 FY | 62.29 Billion KRW | 3.88% |
| 2012 Q2 | - KRW | -100.0% |
| 2011 Q2 | - KRW | -100.0% |
| 2011 FY | 59.96 Billion KRW | 317.17% |
| 2011 Q1 | 14.37 Billion KRW | -4.17% |
| 2011 Q3 | 62.62 Billion KRW | 0.0% |
| 2011 Q4 | 62 Billion KRW | -1.0% |
| 2010 Q3 | 10.62 Billion KRW | -73.14% |
| 2010 Q4 | 15 Billion KRW | 41.18% |
| 2010 Q2 | 39.56 Billion KRW | 0.0% |
| 2010 FY | 14.37 Billion KRW | -70.99% |
| 2009 Q1 | 41.5 Billion KRW | -10.89% |
| 2009 FY | 49.55 Billion KRW | 19.41% |
| 2009 Q4 | 47.27 Billion KRW | 119.87% |
| 2009 Q3 | 21.5 Billion KRW | 0.0% |
| 2009 Q2 | 21.5 Billion KRW | -48.19% |
| 2008 Q2 | 52.73 Billion KRW | 4.79% |
| 2008 Q1 | 50.32 Billion KRW | 24.5% |
| 2008 Q4 | 46.57 Billion KRW | 3.16% |
| 2008 Q3 | 45.14 Billion KRW | -14.38% |
| 2008 FY | 41.5 Billion KRW | -17.53% |
| 2007 Q3 | 40.51 Billion KRW | -11.18% |
| 2007 FY | 50.32 Billion KRW | 95.69% |
| 2007 Q4 | 40.41 Billion KRW | -0.24% |
| 2007 Q2 | 45.61 Billion KRW | 0.0% |
| 2006 FY | 25.71 Billion KRW | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 13.64 Billion KRW | 55.645% |
| Dong-A Socio Holdings Co., Ltd. | 202.06 Billion KRW | 97.006% |
| Ildong Holdings Co., Ltd. | 29.87 Billion KRW | 79.75% |
| HANDOK Inc. | 123.78 Billion KRW | 95.112% |
| Kukje Pharma Co., Ltd. | 475.74 Million KRW | -1171.696% |
| Yuhan Corporation | 60.23 Billion KRW | 89.956% |
| Dong-A ST Co., Ltd. | 161.99 Billion KRW | 96.265% |
| SAMSUNG PHARM. Co., LTD. | 101.81 Million KRW | -5841.987% |
| Hanmi Pharm. Co., Ltd. | 82.02 Billion KRW | 92.625% |
| Hanall Biopharma Co.,Ltd | 590.3 Million KRW | -924.887% |
| Dong Sung Bio Pharm.Co.,Ltd. | 18.52 Billion KRW | 67.337% |
| MYUNGMOON Pharm co.,Ltd | 12.58 Billion KRW | 51.924% |
| Hana Pharm Co., Ltd. | 1.59 Billion KRW | -278.398% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | 55.645% |
| Ilsung Pharmaceuticals Co., Ltd. | 119.67 Million KRW | -4955.215% |
| REYON Pharmaceutical Co., Ltd. | 121 Billion KRW | 95.0% |
| Aprogen pharmaceuticals,Inc. | 32 Billion KRW | 81.094% |
| JW Holdings Corporation | 20.65 Billion KRW | 70.713% |
| Ildong Pharmaceutical Co., Ltd. | 14.82 Billion KRW | 59.191% |
| Chong Kun Dang Pharmaceutical Corp. | 30 Billion KRW | 79.833% |
| JW Pharmaceutical Corporation | 30 Billion KRW | 79.833% |
| Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -2663.049% |
| Hyundai Pharmaceutical Co., Ltd. | 580.64 Million KRW | -941.943% |
| Samil Pharmaceutical Co.,Ltd | 49.56 Billion KRW | 87.795% |
| Jeil Pharmaceutical Co.,Ltd | 4.45 Billion KRW | -35.894% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | 55.645% |
| Kwang Dong Pharmaceutical Co., Ltd. | 19.02 Billion KRW | 68.204% |
| Daewoong pharmaceutical Co.,Ltd | 93.41 Billion KRW | 93.524% |
| JW Pharmaceutical Corporation | 30 Billion KRW | 79.833% |
| Yuhan Corporation | 60.23 Billion KRW | 89.956% |
| Jeil Pharma Holdings Inc | 10.5 Billion KRW | 42.381% |
| Yungjin Pharm. Co., Ltd. | 40.37 Billion KRW | 85.017% |
| Suheung Co., Ltd. | 74 Billion KRW | 91.825% |
| JW Pharmaceutical Corporation | 30 Billion KRW | 79.833% |
| Samjin Pharmaceuticals Co., Ltd. | 4.16 Billion KRW | -45.201% |
| Korea United Pharm Inc. | 10.96 Billion KRW | 44.812% |
| CKD Bio Corp. | 69.43 Billion KRW | 91.286% |
| Daewon Pharmaceutical Co., Ltd. | 34.57 Billion KRW | 82.502% |
| Dongwha Pharm.Co.,Ltd | 16.12 Billion KRW | 62.487% |
| Whan In Pharm Co.,Ltd. | 307.05 Million KRW | -1870.323% |
| Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -2663.049% |
| Chong Kun Dang Holdings Corp. | 72.11 Billion KRW | 91.61% |
| Boryung Corporation | 151.7 Billion KRW | 96.012% |
| Bukwang Pharmaceutical Co., Ltd. | 78.52 Billion KRW | 92.295% |
| Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | 0.0% |
| JW Lifescience Corporation | 168 Million KRW | -3501.19% |